Announcements Trials
Browse Landscape Eligibility

Clinical Trials

5 trials
RecentStart dateEnrollment
mCRPC × Clear all

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 2Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 4Observational 1

Sponsor

Conditions

Breast Neoplasms 12989Neoplasms 10382Carcinoma, Non-Small-Cell Lung 6793Prostatic Neoplasms 6196Colorectal Neoplasms 5862Lung Neoplasms 5040Multiple Myeloma 3541Pancreatic Neoplasms 3511Neoplasm Metastasis 3478Leukemia, Myeloid, Acute 3467Carcinoma, Hepatocellular 3227Ovarian Neoplasms 3138Melanoma 3120Stomach Neoplasms 3019Lymphoma 2970Head and Neck Neoplasms 2575Recurrence 2527Precursor Cell Lymphoblastic Leukemia-Lymphoma 2485Leukemia 2353Colonic Neoplasms 2317Brain Neoplasms 2293Lymphoma, Non-Hodgkin 2257Rectal Neoplasms 2171Uterine Cervical Neoplasms 2164Glioblastoma 1993Leukemia, Lymphocytic, Chronic, B-Cell 1985Carcinoma, Renal Cell 1897Squamous Cell Carcinoma of Head and Neck 1856Lymphoma, Follicular 1829Esophageal Neoplasms 1786

Interventions

enzalutamide 2tislelizumab 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT03395197 2026-04-07

TALAPRO-2

Pfizer

Phase 3 Active not recruiting
1,054 enrolled 21 charts 2 FDA

mCRPC

NCT07389187 2026-02-05

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled

mCRPC

NCT07104643 2025-08-05

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

TYK Medicines, Inc

Phase 1/2 Not yet recruiting
48 enrolled

mCRPC

NCT07096128 2025-07-31

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

Chinese PLA General Hospital

Phase 1 Recruiting
36 enrolled

mCRPC

NCT06830408 2025-02-17

Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study

University Hospital, Basel, Switzerland

Completed
250 enrolled

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡